Presented at #ESMO26: In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. Full phase 3 VOLGA trial results: nej.md/4z7dQFm @myESMO

Calling all Alliance members and researchers! Register now for the Fall 2026 Group Meeting (Nov 4-6, 2026). Don't miss out on advancing cancer clinical trials together! ➡️ View registration and schedule at bit.ly/FallGroup2026 #Oncology #ClinicalTrials #CancerCare

Calling all Alliance members and researchers! Register now for the Fall 2026 Group Meeting (Nov 4-6, 2026). Don't miss out on advancing cancer clinical trials together! ➡️ View registration and schedule at bit.ly/FallGroup2026 #Oncology #ClinicalTrials #CancerCare

Today marks the beginning of a new era in cancer care. Alongside leaders from across the Commonwealth, the @CityOfBoston, @BIDMChealth, and the broader community, we broke ground on the Lavine Bekenstein Hospital at Dana-Farber. This 450,000-square-foot facility will include 300 inpatient beds across 10 floors and has been designed specifically around the needs of people with cancer and their families. Built to support the next generation of cancer treatment, the hospital will bring together world-class clinical care, groundbreaking research, and advanced technology on a single, integrated campus. This hospital was made possible through a joint philanthropic commitment from Josh and Anita Bekenstein and the Jonathan and Jeannie Lavine family. This transformational gift—the largest single gift in our history—builds on both families’ decades-long dedication to our mission: delivering expert, compassionate patient care while accelerating discoveries that improve outcomes for people with cancer around the world. Located along Brookline Avenue, the hospital will become the centerpiece of a closely coordinated campus linking Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and @HMFPBoston. The facility has been designed to accommodate rapid advances in oncology, providing flexible clinical space capable of adapting to future innovations in cancer treatment and research. Learn more about this historic ceremony: bit.ly/4zEk3YZ

GO CANES, SAY IT BACK‼️

LETs go CANES! Beat FSU and stay undefeated! 🙌🏼🙌🏼 @UM_alumni @univmiami

FDA approves new treatment option, #atezolizumab in combination with chemotherapy, for patients with stage III dMMR #coloncancer based on results from the phase III #ATOMIC trial led by @ALLIANCE_org. Learn more: bit.ly/FDA-ATOMIC @theNCI #NCTN #CancerResearch #CRCsm

Discover the latest advances in breast, lung & prostate cancer care! Join the Alliance for a free public webinar on Oct 1 featuring leading researchers & patient advocates sharing key findings from #ASCO26. Register now: bit.ly/Alliance-Webinar-Oct2… #clinicaltrials

Since daraxonrasib's FDA approval, I have enjoyed reading my mentor, Dr. Robert Mayer's words to @CancerHistProj about pancreatic cancer: decades of "swings, misses, foul balls, and finally a direct hit." That's what sustained NCI investment looks like: shorturl.at/sTItt

September is #ProstateCancerAwarenessMonth! 💙From precision diagnostics and targeted therapies to telehealth exercise programs, Alliance clinical trials are driving the next generation of cancer care. Learn more about our current trials at 👇 bit.ly/Prostate2026 #pcsm

Thrilled to have joined @DanaFarber and to be working with an inspiring leader in oncology, @DrChoueiri. Delighted to serve as a faculty medical oncologist and Co-Director of the @Harvard Cancer Consortium #ProstateCancer Program. Excited for this new chapter!

Now enrolling! The Alliance A032303 (GAIN-BCG) trial is testing whether adding gemcitabine, a chemotherapy drug, to BCG, a #bladdercancer immunotherapy, can help prevent high-grade non-muscle-invasive bladder cancer from coming back. Visit bit.ly/Alliance-GAIN-BCG #NCI #NCTN

Now enrolling! @ThomasHopeMD of @UCSFHospitals and Deaglan McHugh of @MSKCancerCenter lead Alliance A032304 (RECIPROCAL), a phase III study to optimize targeted radiation therapy to minimize side effects while preserving efficacy in prostate cancer bit.ly/AllianceA032304

Once a Cane, always a Cane. 🙌   For some families, becoming a Cane runs in the family! 🧡💚   This week, Hurricanes legend Ed Reed, B.L.A. ’02, and UM parent, welcomed our newest Canes to the UM family - the children and grandchildren of University of Miami alumni who are starting at the U this fall.   At the annual legacy welcome reception, Ed reminded us what it truly means to be a Cane for life. Joined by Executive Vice President for Academic Affairs & Provost Joel Samuels; Senior Vice President for Student Affairs and Alumni Engagement Pat Whitely, Ed.D. ’94; UM Alumni Association Board of Directors President Darren Dupriest, B.B.A. ’91; President-Elect David Mullings, B.S. ’00, M.B.A. ’03; among other university leaders, the evening celebrated multi-generations of Canes all united by one bond – the U.   We can’t wait to see the impact the next generation of Canes will have and watch the legacy continue. #CanesForLife #CaneKickOff2026 #HurricaneLegend

Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by @usnews. Learn more: bit.ly/3TDL9Qi

15 Posts Not To Miss From the 2026 Bladder Cancer Advocacy Network Think Tank @BladderCancerUS @DrOmarMian @FaltasLab @UroDocAsh @katy_beckermann @Parminder1699 @LauraBukavinaMD @PGrivasMDPhD @DrKarineTawagi @apolo_andrea @bergsa83 @akfsurgeon @BrendanGuercio @shilpaonc @DrAndreKydd oncodaily.com/not-to-miss/bc…

🎉 Registration for our 2026 International Kidney Cancer Symposium (IKCS): North America is open! #IKCSNA26 Early registration rates available now. We're excited to welcome you to Dallas! Reserve your spot to join us 👉 web.cvent.com/event/885b2adb…

Great breakout session on treatment de-intensification for #bladdercancer, less is more! #BCANTT26 The emphasis on bladder preservation and evolving risk-adapted role of radical therapies is great for patients. @KMittalmd @snseyedinMD @bergsa83 @abhinav__khanna @BladderCancerUS

#BCANTT26 discussion of ctDNA in clinical trials @alantanmd @LauraBukavinaMD @mouwlab @DrJohnSfakianos essential for personalized treatment selection, monitoring & treatment Ultra sensitive ctDNA = future in solid tumors @TempusAI @NateraOncology assays discussed

Looking forward to @BladderCancerUS BCAN Think Tank this week; presenting at the “Less Is More” breakout session chaired by @bergsa83 and @ClintonTim Excited to discuss how evidence is reshaping treatment de-escalation #BCANThinkTank @Parminder1699 @PGrivasMDPhD @MonikaJoshimd